Printer Friendly
The Free Library
19,585,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioTime Announces Allocation of Over-Subscription Shares Sold in Rights Offer.


BERKELEY Berkeley (bûr`klē), city (1990 pop. 102,724), Alameda co., W Calif., on the E shore of San Francisco Bay just N of Oakland; inc. 1878. Originally (1820) part of a Spanish rancho, the site was purchased by Americans in 1853. , Calif.--(BW HealthWire)--March 24, 1999--BioTime, Inc. (Nasdaq:BTIM) announced the proration Proration

A situation during a corporate action in which the available cash or shares are not sufficient to satisfy the offers tendered by shareholders. Therefore, a proportion of both cash and shares is granted for each offer tendered.
 of shares available for sale to persons who exercised the over-subscription privilege in BioTime's recently completed rights offer.

The rights offer was heavily over-subscribed. The holders of 5,318,099 shares requested more than 1,000,0000 shares through the exercise of the over-subscription privilege. However, only 270,085 shares were available to fill over-subscriptions.

Shareholders who properly exercised the over-subscription privilege were allocated over-subscription shares based upon the ratio of the number of rights issued to them. Each shareholder was issued one right for each BioTime share they owned.

On the average, shareholders who exercised their over-subscription privilege were able to purchase in the rights offer (including the shares issued upon the exercise of the rights issued to them and the shares purchased through the over-subscription privilege) a total number of shares equal to approximately 11.7% of the number of shares they owned before the rights offer.

BioTime, headquartered in Berkeley, is engaged in the research and development of blood plasma blood plasma
n.
The yellow or gray-yellow, protein-containing fluid portion of blood in which the blood cells and platelets are normally suspended.
 volume expanders, blood replacement solutions during hypothermic hy·po·ther·mi·a  
n.
Abnormally low body temperature.



[hypo- + Greek therm
 (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, the preservation of organs awaiting transplant transplant
 or graft

Partial or complete organ or other body part removed from one site and attached at another. It may come from the same or a different person or an animal. One from the same person—most often a skin graft—is not rejected.
, and other applications.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Mar 25, 1999
Words:207
Previous Article:REPEAT/Pacific Life Reports Strong 1998 Financial Results.
Next Article:TouchStone Software Announces CheckIt NetOptimizer Bundling Agreement With Diamond Multimedia.
Topics:



Related Articles
FDA Completes Review of BioTime's New Drug Application for Hextend, BioTime Pleased With Quick Response.
BioTime Files for Rights Offering.
BioTime Commences Rights Offer.
BioTime Raises Over $7.3 Million in Rights Offer; Announces That Rights Offer was Heavily Over-Subscribed.
Hextend Sales Begin, BioTime Receives Milestone Payments.
BioTime, Inc. Moving From Nasdaq to the American Stock Exchange, Symbol Changes to 'BTX'.
BioTime Files for Canadian Regulatory Approval of Hextend.
NPBI Manufactures BioTime's HexTend for European Approval.
Organon Teknika and BioTime Announce Exclusive License Agreement for Hextend.
BioTime to Seek New International Marketing Partner.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles